Skip navigation
Watchlist Sponsored By :
  • 10 States for Cheapest Gas

      With consumers feeling the pain at the pump this summer, what states rank among the cheapest for a gallon of regular unleaded on average?

  • 10 Recession-Proof Jobs

      Despite a slowing economy and layoffs in many industries, certain professions remain in high demand and are expected to weather a recession better than others.

  • Stock Picks for Your 20's

      The sinking stock market is enough to scare off most investors, let alone those in their 20s. Here are picks for Twenty-Somethings using a five year time horizon.

  • Texas is Tops in 2008

      Texas knocked out last year's top state for business, Virginia. How did your state fare in our annual study?

  • Powering the Planet

      Energy has become the most common denominator in the global economy. Ultimately, it may be the great unifier. After all, imagine a world without energy, affordable energy.

  • Apple & The New iPhone

      Second acts should not be taken for granted. Apple and Steve Jobs have yet to make that mistake and they're unlikely to do so with the launch of the new iPhone.

5-Star Picks: Net and Biotech Plays
By Andrew Fisher | 13 Mar 2008 | 11:41 AM ET
Font size:

Picks and Pans

At least two five-star fund managers are looking past this week's market gyrations and offering investors what they think are some promising stock opportunities.

Michael Lippert of Baron Funds focuses on some Internet-related equities, while Michael Cuggino of Permanent Portfolio Funds sees biotech as a buy.

Lippert likes online diamond retailer Blue Nile [NILE  Loading...      ()   ].

"They're taking massive share from their competition," he told CNBC.  "The online business model is just better than the offline model."

He also recommends Equinix [EQIX  Loading...      ()   ].

"They operate data centers that act as on-ramps of the Internet, so everything that's driving Internet growth is driving their business," he said.

Cuggino's biotech names include Amgen [AMGN  Loading...      ()   ].

"On Aranesp, we're hearing some news out of the FDA today," he said.

Aranesp and other anti-anemia drugs had combined sales of more than $6 billion last year.

"Genentech [DNA  Loading...      ()   ]'s another good name, especially recently, with their news on Avastin for breast cancer," he added. 

The government's approval of Avastin to treat breast cancer earlier this year came as something of a surprise.  Avastin had already been approved for the treatment of lung and colon cancer.

"Biotech's an area that's a little bit more defensive, but still hasn't participated in growth over the last several years, so it should, going forward," Cuggino said.

Disclaimer

© 2008 CNBC.com

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis